Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Verrica Pharmaceuticals ( (VRCA) ).
On August 8, 2025, Verrica Pharmaceuticals announced it had regained compliance with Nasdaq listing requirements. The company reported $12.7 million in revenue for Q2 2025, driven by strong growth in YCANTH sales and milestone payments from Torii Pharmaceutical. Verrica is preparing for a Phase 3 program for VP-315 for basal cell carcinoma and anticipates further growth through strategic partnerships and regulatory approvals. A reverse stock split was also effected on July 24, 2025, reducing the number of shares outstanding.
The most recent analyst rating on (VRCA) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals faces significant financial challenges, with persistent losses and negative equity being major concerns. Technical indicators suggest a bearish trend, and the valuation is unattractive due to negative earnings. However, recent corporate events provide some optimism, as strategic initiatives aim to stabilize the company’s financial position.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology therapeutics company that develops and sells medications for skin diseases requiring medical interventions. The company focuses on products like YCANTH for molluscum contagiosum and is advancing treatments for common warts and basal cell carcinoma.
Average Trading Volume: 48,335
Technical Sentiment Signal: Sell
Current Market Cap: $61.97M
Find detailed analytics on VRCA stock on TipRanks’ Stock Analysis page.